Floatz logo

Dapagliflozin

Arteriosclerosis Disorder

University Medical Centre LjubljanaSmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Arteriosclerosis Disorder cohort.

Asset / SponsorPhaseRating
Glibenclamide
University of Campinas, Brazil
Phase 4BB
Aspirin
Yonsei University
Phase 4BB
Dipyridamole
UMC Utrecht
Phase 4BB
CLOPIDOGREL
Yonsei University
Phase 4BB
Apixaban
Yonsei University
Phase 4BB

View all 10 →

Same molecule, other indications

Dapagliflozin is also rated in:

type 2 diabetes mellitusActive
BBB
Indicative · Phase 4
78 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseActive
BBB
Indicative · Phase 4
77 / 100
View asset →
diabetes mellitusActive
BB
Indicative · Phase 4
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →